Clinical trial
A Phase III Study to Evaluate the Efficacy of INM004 (Shiga Antitoxin) in Pediatric Patients With Shiga Toxin-producing Escherichia Coli-associated Hemolytic Uremic Syndrome.
NCT06389474 is registered in ClinicalTrials.gov with Inmunova S.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Study to Evaluate the Efficacy of INM004 (Shiga Antitoxin) in Pediatric Patients With Shiga Toxin-producing Escherichia Coli-associated Hemolytic Uremic Syndrome.
- Lead sponsor
- Inmunova S.A.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- October 5, 2024
- Completion date
- December 31, 2026
- Enrollment
- 220 (estimated)
- Sites
- 52
Conditions
As the registry lists them; a condition with its own page is linked.